Disease Landscape and Forecast Insights

With its launch in August 2016, Zinbryta became the 14thdisease-modifying therapy (DMT) approved to treat relapsing forms of multiple sclerosis (MS) in the United States. The monoclonal antibody…

Immune (idiopathic) thrombocytopenic purpura (ITP) is a hematological autoimmune disorder characterized by low platelet count in the blood, which may lead to easy bruising and bleeding. ITP has an…

Fewer than ten new brands have launched in the highly generic and crowded Parkinson’s disease (PD) therapy market during the past two decades, but PD’s large and growing elderly population and…

Abstract: Hepatocellular carcinoma is the most common form of liver cancer. It is the seventh-most-common type of cancer worldwide and the third-most-common cause of cancer death worldwide. Most…

The HIV therapy market is very dynamic. Over the last decade, many effective antiretroviral (ARV) therapies have been introduced, prompting changes in treatment guidelines and clinical…

Amyloidosis refers to the disruption and damage to organs and tissues due to deposits of abnormal, insoluble amyloid fibrils, which are formed by the accumulation of misfolded proteins. Amyloid…

The hepatitis C virus (HCV) therapy market has been marked by tremendous growth and has undergone a rapid evolution of the treatment landscape with the launch of novel direct-acting antivirals (…

From disease basics to insightful analysis of market dynamics, Thyroid Carcinoma | Niche Disease Landscape & Forecast | United States, EU5 provides comprehensive disease coverage addressing…

Antibody drug conjugates (ADCs) are a class of drug therapies that combine the targeting abilities of monoclonal antibodies with the cancer-killing activities of cytotoxic agents. ADCs can…

Huntington’s disease (HD) is a neurodegenerative genetic disorder caused by an abnormal trinucleotide repeat in the Htt gene. Aggregation of the product of the mutant allele, mHtt, drives the…

Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important gram-positive pathogen found in both the hospital and outpatient settings. The newly marketed oritavancin (The Medicine…

The therapeutic landscape for second-line chronic lymphocytic leukemia (CLL) has benefited from the introduction of three new therapies since 2014, namely, Imbruvica, Venclexta, and Zydelig…